Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2015-2025
Analysis of revenues and R&D prospects for those eye drugs – you explore potentials What’s the future for treating disorders of the retina? Visiongain’s updated study forecasts those pharma revenues. There you find outlooks for sales growth in that industry. You also explore trends, technologies, therapies and opportunities.
That report gives revenue predictions to 2025 at overall world market, submarket, product and national level. So avoid falling behind in data or losing influence. Instead find what’s happening for those eye medicines. Discover, from 2015, what’s possible.
There gain technological, clinical and commercial outlooks. Read on to explore those ophthalmic pharmaceuticals and see what future revenues they could generate.
Forecasts and other analysis to benefit your research, assessments, plans and decisions
There explore prospects for companies developing, producing and marketing drugs for wet age-related macular degeneration (AMD or ARMD), dry AMD, diabetic retinopathy (DR) and other rear eye disorders. Discover present trends and future possibilities.
Besides revenue forecasting to 2025, our new work shows recent results, sales growth rates and market shares. There you find original analysis. Explore research and development too, seeing prospects. Also get 42 tables, 46 charts and two research interviews.
That survey also covers geographic atrophy (GA), diabetic macular oedema/edema (DME), proliferative and non-proliferative diabetic retinopathy (PDR and NPDR) and retinal vein occlusion (RVO). Avoid missing out on original data and discussions to help your work.
Ophthalmic technology – find sales growth opportunities and how to help your work
Stay ahead, then, in knowledge. Our study’s purpose is to benefit your research, analyses and decisions.
There find the most promising and lucrative treatments for neovascularisation and other retinal diseases from 2015.
The future holds great promise for organisations treating those rear eye disorders. Discover the progress and high gains possible there, avoiding struggles to find business information you need. See how patients, healthcare providers and companies can benefit.
And the following sections explain what you get in that new investigation.
Forecasting the world market and segments for medicines treating retinal disorders
What’re the secrets of that technology's progress? What’s its potential? Find in our report overall world revenue to 2025 for retinal medicines – existing, emerging and expected drugs.
Also explore individual revenue predictions to 2025 for four therapeutic submarkets at world level:
Advanced Cell Technology (now Ocata Therapeutics)
Aldexa (previously Neuron Systems Inc.)
American Academy of Ophthalmology
American Society of Retina Specialists
Applied Genetic Technologies
Association for Research in Vision and Ophthalmology (ARVO)
Autorità Garante della Concorrenza e del Mercato (Italian Competition Authority)
Autorité de la concurrence (French Competition Authority)
Bayer Yakuhin (Bayer subsidiary)
Casey Eye Institute at Oregon Health and Science University
Cell Cure Neurosciences (a subsidiary of BioTime)
Cellular Dynamics International
Center for iPS Cell Research and Application
Chengdu Kanghong Biotech
China Food and Drug Administration
Elseiver Business Intelligence
ES Cell International
European Court of Justice
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
General Medical Council (GMC, UK)
Human Genome Sciences
Innovations in Sight
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG, Germany) International Diabetes Foundation
Institute of Ocular Pharmacology
iPS Academia Japan
Kaplan Medical Center
Ludwig-Maximilians - University of Munich
Merck & Co.
Ministry of Health, Labour and Welfare (Japan)
National Eye Institute (NEI, US)
National Health Service (NHS, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
Neuron Systems Inc. (now Aldexa)
Numoda Capital Innovations
Oklahoma Medical Research Foundation
OncoCyte (a subsidiary of BioTime)
OrthoCyte (a subsidiary of BioTime)
Österreichische Agentur für Gesundheit und Ernährungssicherheit (AGES, Austria)
Pele Nova Biotecnologica
ReCyte Therapeutics (a subsidiary of BioTime)
Retina Macula Institute
Sanwa Kagaku Kenkyusho
Singapore National Eye Centre
Stemedica Cell Technologies
SV Life Sciences
Teva Pharmaceutical Industries
Third Rock Ventures
University of Kentucky College of Medicine
University of Kyoto
University of Virginia
World Health Organization (WHO)